Previous close | 37.47 |
Open | N/A |
Bid | 34.60 |
Ask | 39.50 |
Strike | 175.00 |
Expiry date | 2025-01-17 |
Day's range | 37.47 - 37.47 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Novo Nordisk (NVO) announces positive top-line results from its phase III increased dosage study of semaglutide, 25 mg and 50 mg, for the treatment of patients with type II diabetes.
Bagsværd, Denmark, 27 March 2023 – On 1 February 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 28 billion to be executed during a 12-month period beginning 1 February 2023. Under the programme i
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.